N/A N=1,705

Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)

Hypertension

Bottom Line

View on ClinicalTrials.gov: NCT01368185 ↗

Enrolled (actual)

1,705

Serious AEs

0.0%

Results posted

Sep 2011

Primary outcome: Primary: Serum Uric Acid (SUA) Level — 6.4; 6.6 mg/dL — p=<0.01

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 20+ yrs
Sex: All
Sponsor: Organon and Co
Primary completion: Aug 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Serum Uric Acid (SUA) Level	6.4; 6.6	<0.01 sig
SECONDARY The Percentage of Patients With Hyperuricemia	27.0; 14.6	<0.0001 sig
SECONDARY Diastolic Blood Pressure (DBP)	89; 81	<0.01 sig
SECONDARY Systolic Blood Pressure (SBP)	150; 135	<0.01 sig

Summary

This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid levels.

Eligibility Criteria

Inclusion criteria

Participant was >20 years and 2 mg/dL

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01368185). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.